BNC-210

BNC210 (also known as IW-2143 during its time licensed to Ironwood Pharmaceuticals) is an anxiolytic drug that acts via negative allosteric modulation of the α7-nicotinic acetylcholine receptor,[1] by Bionomics Limited. It is currently being investigated for the treatment of post traumatic stress disorder.[2] The drug has demonstrated clinically significant anxiety reduction in both animal models and in Phase I trials.[3]

BNC-210
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC17H23N3O3
Molar mass317.389 g·mol−1
3D model (JSmol)

It appears to be devoid of significant sedation or memory-impairing side effects, as well as lacking addictive potential in rat discriminatory models.[4]

Phase I trials have shown no serious side effects.

Bionomics previously licensed it to Ironwood Pharmaceuticals in January 2012, where it was known as IW-2143. In December 2012, IW-2143 begun undergoing phase I clinical trials in the United States,[5] but in November 2014, was released back to Bionomics in a mutual agreement.[6] Bionomics will now continue development and clinical testing, with Ironwood receiving a royalty for their work done.

As of April 2015, BNC210 is in phase II clinical trials.[7] The estimated study completion date is September 2018. [2]

Study Details

The clinical trial is currently testing twice daily oral dosages of 600 mg, 300 mg, and 150 mg, for 12 weeks. [2] The primary objective of the trial is for the treatment of PTSD with a secondary objective for the effectiveness in treating anxiety disorders and depression. [2]

gollark: Computer stuff just tends to have hilariously stupid amounts of security vulnerabilities in everything, and brains at least... probably less so, since most of them would require physical access probably maybe hopefully.
gollark: Apparently?
gollark: No, you consume it too sometimes.
gollark: Yes, I probably wouldn't trust any complicated computer stuff with much brain access, realistically.
gollark: Why not connect your brain to <@160279332454006795>'s heavdrone™s?

See also

References
  1. http://www.bionomics.com.au/upload/investors/asx-announcements/4736/ASX695%20%20BNC210%20Phase%201b%20initiation.pdf
  2. Clinicaltrials.gov. "www.clinicaltrials.gov" (HTML). Clinicaltrials.gov. Retrieved 2018-01-04.
  3. "Bionomics - Pipeline". Retrieved 2010-11-09. Bionomics has discovered a novel compound, BNC210, that offers dramatic competitive advantages over existing treatments
  4. O'Connor, S.; Andriambeloson, E.; Huyard, B.; Wagner, S.; Sleebs, B.; Quasi, N.; Bui, C.; Street, I. "BNC210: A Novel Compound with Potent Anxiolytic Activity" (PDF). Bionomics Limited. Retrieved 2010-11-09. By applying a targeted medicinal chemistry strategy beginning from a compound cited in the literature, Bionomics has developed BNC210
  5. "Archived copy". Archived from the original on 2014-05-04. Retrieved 2013-02-01.CS1 maint: archived copy as title (link)
  6. http://www.biotechdaily.com.au/media/backissues/2014/11%20Nov/BD%20Biotech%20Daily%20Nov%2011.pdf
  7. Bionomics Limited. "www.prnewswire.com" (HTML). PRNewswire. Retrieved 2015-06-10.



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.